** Shares of biotech firm Patrys fall 50% to A$0.003, a record low

** Stock posts biggest intraday pct fall since Nov. 11, 2008

** Co says cancer therapy antibody PAT-DX1 did not pass some parameters in production

** Adds, it will not use the produced batch for planned Phase-1 clinical trial in cancer patients

** Says it will now pivot towards developing therapeutic possibilities for its other antibody, PAT-DX3

** About 24 mln shares change hands, ~28x the 30-day avg volume

** PNB down ~63% YTD

(Reporting by Kumar Tanishk in Bengaluru)

((Tanishk.Kumar@thomsonreuters.com;))